Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech companyin a deal valued at approximately $10 billion.
The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.
The acquisition sparked a sharp rally in CRNX stock.
CRNX shares climbed nearly 100% in pre-market trading on Tuesday to around $83.69.
Vertex shares, meanwhile, declined modestly following the announcement.
The transaction comes amid a wave of pharmaceutical industry acquisitions, as large drugmakers seek to strengthen their development pipelines by acquiring smaller biotechnology companies with promising therapies.
Vertex targets endocrinology growth
According to a joint press release, Vertex expects Crinetics’ portfolio, including its approved acromegaly treatment Palsonify and investigational therapy Atumelnant, to contribute an estimated $5 billion in peak annual sales.
Crinetics focuses on therapies for endocrine disorders.
The company markets Palsonify, a once-daily oral treatment approved by the US Food and Drug Administration in September for acromegaly, a rare hormonal disorder caused in most cases by a noncancerous pituitary gland tumour that leads to excessive growth hormone production during adulthood.
The disease can result in enlargement of the face, jaw, hands, and feet, along with symptoms including joint pain, headaches, and nausea.
Crinetics said Palsonify works by lowering insulin-like growth factor to help alleviate these symptoms.
The company’s pipeline also includes Atumelnant, a once-daily oral treatment under development for congenital adrenal hyperplasia (CAH), a group of inherited disorders affecting the adrenal glands.
The condition leads to excessive production of male sex hormones known as androgens.
Patients with CAH are commonly treated with high-dose glucocorticoids, which are associated with multiple side effects.
Crinetics is developing Atumelnant as an alternative treatment approach.
The company also said the therapy has demonstrated potential in treating Cushing’s syndrome, a rare hormonal disorder characterised by excessive cortisol levels that can cause rapid weight gain, muscle weakness, bruising and high blood pressure.
CEO highlights strategic fit
Vertex Chief Executive Officer Reshma Kewalramani described the acquisition as strategically aligned with the company’s long-term growth plans.
“Its focus on serious diseases in specialty markets with significant unmet need, well-understood causal human biology, and potentially best-in-class medicines could deliver transformative benefit to patients,” she said in a statement.
Kewalramani added that Vertex intends to build on its experience in rare genetic diseases to continue expanding the commercial potential of Palsonify.
Vertex has established its business around treatments for cystic fibrosis and has also expanded into gene-editing therapies through its partnership with CRISPR Therapeutics.
Premium reflects pipeline potential
Crinetics closed at slightly above $42 per share before the announcement, meaning Vertex’s offer represents a premium of more than 100%.
According to the companies, the acquired portfolio could generate approximately $5 billion in peak annual sales.
Vertex reported total revenue of $12 billion last year, making the acquisition a significant addition to its long-term growth strategy.
Market analysts also viewed the strategic rationale positively.
Citi analyst Geoff Meacham said the acquisition aligns well with Vertex’s existing strengths in specialty diseases and biologically targeted medicines.
“The fit is clear, given existing expertise in specialty markets, serious diseases, causal biology, and measurable biomarkers. The $5 billion peak sales framing adds another route to sustain double-digit topline growth.”
Meacham maintained a Buy rating on Vertex and set a price target of $585, indicating further upside from the stock’s previous closing level.
The post Crinetics shares surge after Vertex agrees to $10B cash buyout appeared first on Invezz
